UNC Health Medication Formulary
Add Formweb to your mobile device
UNC Health Medication Formulary
System Formulary Update
Pegfilgrastim (Neulasta OnPro)
Situation
The formulary restriction proposal for pegfilgrastim (Neulasta OnPro) was approved at the April 2022 System P&T Committee meeting.
Background
The following medications were reviewed via a medication use evaluation: Pegfilgrastim (Neulasta OnPro) and pegfilgrastim biosimilars
Assessment/Recommendation
Change effective: Tuesday, May 24th
System P&T voted to approve the following restriction criteria for pegfilgrastim (Neulasta OnPro):
- Use of Neulasta Onpro is restricted to patients in outpatient encounters or clinic use only (i.e. no inpatient use) who meet one of the following criteria:
- Initiation of therapy in patients with insurance restrictions that do not cover Ziextenzo or Udenyca injection, or require use of Neulasta OnPro
- Continuation of therapy in patients who previously received Neulasta OnPro injection
- Transportation issues causing financial hardship
- Facility bound where the facility will not transport 2 days in a row
- Live greater than 45 miles from a treatment/infusion center
Note: Stock of this formulary product may vary at individual entities